<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Poster 2696: Anti-PD-1 Induced Microbiota Changes

Anti-PD-1 mAb Treatment Induces Significant Gut Microbiota Changes in the CT-26 Colon Cancer Syngeneic Model

Jian Ding, Xiangchao Gu, Juan Zhang, WenQing Yang, and Qian Shi
CrownBio 2017. Poster 2696. Anti-PD-1 Induced Microbiota Changes
Increasing evidence has shown that gut microbiota play an important role in shaping systemic immune response.

A growing number of studies have revealed how gut microbiota change immune response and influence the efficacy of anticancer immunotherapeutics, e.g. anti-CTLA-4 and anti-PD-L1 antibody treatment, both in laboratory and clinical settings.

The potential immuno-modulatory roles of gastrointestinal microbiota during preclinical immunotherapy evaluation have now been evaluated, focusing on anti-PD-1 treatment.

Read this Poster to Discover:

  • How anti-PD-1 treatment induces significant profile changes in the gut microbiota of the CT-26 syngeneic tumor model – with both up- and down-regulation of gut bacteria

  • That gut microbiota modulation is linked with potential immune-microenvironment changes in the context of immuno-oncology

  • How the gut microbiome could be used either as a biomarker to differentiate responders from non-responders in cancer immunotherapy, or as a potential alternative to cancer therapeutics

Download the Poster Now!

Download Now

Your privacy is important to us.
We'll never share your information.